Know Labs Inc

Know Labs, Inc. engages in the development, marketing, and sale of a photonics technology. It offers its product under the ChromaID brand. The firm operates through the following segments: The Development of Bio-RFID and ChromaID Technology, Particle, Inc. Technology, and AI Sales of NFT Products. Know Labs was founded by Ronald Peter Erickson on October 8, 1998 and is headquartered in Seattle, WA.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Know Labs Inc reports improved Q1 performance amidst leadership changes

Know Labs Inc's Q1 2023 earnings call highlighted improved financial performance, progress on Bio-RFID technology, and reassurance of continued momentum despite leadership changes.
The company's strengths lie in innovation, strategic partnerships, and a focus on glucose monitoring, while facing challenges in regulatory approvals and leadership transitions.
Opportunities for Know Labs include diversifying their analyte identification capabilities, leveraging manufacturing partnerships, and capitalizing on the demand for healthcare innovation.

Know Labs reports Q3 loss but shows promise in innovation

Know Labs showcased progress in innovation and research, with a focus on reducing the burn rate. However, challenges include the net loss in Q3 2023 and the need to address market cap concerns. Opportunities exist in leveraging strategic partnerships and potential FDA approvals for future growth.

Know Labs Inc reports Q3 achievements, navigates financial challenges

Know Labs Inc demonstrated strong performance in Q3 2023, with notable achievements in technology development, clinical testing, and IP portfolio expansion.
While facing financial challenges and regulatory hurdles, the company's strategic focus on innovation and cost management positions it for future growth and success.
By leveraging opportunities in data collection, regulatory strategy, and fundraising, Know Labs Inc aims to drive innovation and achieve key milestones in the coming quarters.

Know Labs reports improved FY 2023 performance and unveils Generation 2 device

Know Labs Inc showcased strong financial and operational performance in FY 2023, underpinned by strategic advancements and prudent financial management.
While challenges exist in product development and cost management, the company's focus on innovation and market validation bodes well for future growth.
With a positive outlook for FY 2024 and a clear roadmap for product development, Know Labs is poised to capitalize on market opportunities and drive value for stakeholders.

Know Labs advances noninvasive glucose monitoring with strong IP portfolio

Know Labs Inc (KNW) demonstrated progress in technology development, financial management, and strategic planning during Q1 2024.
While facing challenges in burn rate management and market competition, the company's strong IP portfolio and clinical focus present growth opportunities.
Overall, Know Labs shows promise in innovation, financial stability, and market expansion, positioning itself for future success in the medical device sector.

Know Labs reports strong Q2 performance with promising product launches

Know Labs Inc demonstrated strong performance in Q2 2024, marked by financial improvements, successful product launches, and promising clinical trial results.
The company's strengths lie in innovation, intellectual property, and operational efficiency, positioning them well for future growth and market success.
Challenges around financing, regulatory approvals, and market competition require strategic focus and proactive management to capitalize on growth opportunities.
Opportunities in international expansion, product development, partnerships, and regulatory compliance offer avenues for Know Labs to drive revenue and market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SEATTLE--(BUSINESS WIRE)--Know Labs Announces Expanded Technology Leadership in its Executive Team; Acceleration of Platform Development to Secure Strategic Partnerships.

Know Labs Announces Expanded Technology Leadership in its Executive Team

SEATTLE--(BUSINESS WIRE)--Know Labs Sensor Technology in Steering Wheels Could Curb Impaired Driving. Know Labs Retains Stanbridge Group to Secure Automotive JV Partnerships.

Know Labs Sensor Technology in Steering Wheels Could Curb Impaired Driving

SEATTLE--(BUSINESS WIRE)--Know Labs Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards. A Plan for Compliance has been undertaken.

Know Labs Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

SEATTLE--(BUSINESS WIRE)--Peer-reviewed journal publication validates Know Labs' proprietary technology and its application for non-invasive blood glucose monitoring.

Know Labs Study Published in IEEE Sensors Journal

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW) (the “Company”), a leading developer of non-invasive medical diagnostic technology, today announced that it has entered into definitive agreements with certain investors to purchase 6,365,385 Units for an aggregate offering of $1.655 million at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of.

Know Labs, Inc. Announces $1.655 Million Public Offering

Know Labs, Inc. (NYSE:KNW ) Q3 2024 Results Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Ron Erickson - Chairman and Chief Executive Officer Peter Conley - Chief Financial Officer and Senior Vice President, IP Conference Call Participants Operator Greetings. Welcome to Know Labs's Third Quarter 2024 Earnings Conference Call.

Know Labs, Inc. (KNW) Q3 2024 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter of the fiscal year 2024 ended June 30, 2024. Financial Highlights: In Q3 FY 2024, Know Labs reported a net loss of $4.10 million dollars, compared to a net loss of $3.60 million dollars in Q3 FY 2023, an increase in net loss of 13.9%. This translates to earnings per share of a loss of $0.05, better than the prio.

Know Labs, Inc. Reports Third Quarter FY 2024 Results

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostics technology, today announced the successful closing of its previously announced underwritten public offering of 13,250,000 units at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of $0.26, and the partial exercise of the underwriters' opt.

Know Labs, Inc. Announces Closing of $3.445 Million Public Offering

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW) (the “Company”), a leading developer of non-invasive medical diagnostic technology, today announced the pricing of a firm commitment underwritten public offering of 13,250,000 units at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of $0.26 (the "Offering"). The aggregate gross proceeds from t.

Know Labs, Inc. Announces Pricing of $3.445 Million Public Offering

BRISBANE, Australia--(BUSINESS WIRE)--Sandbox VR, a full-body virtual reality entertainment experience, is pleased to announce the grand opening of its first Australian location on Thursday, August 15, on the Gold Coast. Sandbox VR Gold Coast is the 50th to open since the company launched in 2017. With over 100k players monthly, Sandbox VR is rapidly growing its global footprint with thriving corporate-owned locations and a robust franchising program. Tickets are on sale now and all guests who.

Sandbox VR Opens First Australian Location August 15 in Gold Coast

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its third quarter of the fiscal year 2024 ended on June 30, 2024, on August 14, 2024, beginning at 1:30 pm PT. Media and investors may access the live audio webcast at this link and also at https://ir.knowlabs.co, beginning at 1:15 pm PT. The webcast will also be available for replay a.

Know Labs, Inc. to Host Review of Third Quarter Fiscal Year 2024 Results on August 14, 2024

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today announced the publication of its peer-reviewed study in Diabetes Technology & Therapeutics Journal titled, “A Glycemic Status Classification Model Using a Radiofrequency Noninvasive Blood Glucose Monitor.” Diabetes Technology & Therapeutics is a leading, peer-reviewed journal covering all aspects of diagnosing and managing diabetes with cutting-edge de.

Know Labs Publishes Clinical Results in Leading Diabetes Journal

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today announced further interim results from a clinical research study that assessed the accuracy of Know Labs' proprietary non-invasive radiofrequency (RF) dielectric sensor in measuring blood glucose. Participants with prediabetes and Type 2 diabetes were studied and venous blood was used as a comparative reference. The study found that the accuracy of Know Labs'.

Know Labs to Present at the American Diabetes Association's Scientific Sessions

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today announced that it has joined the Industrial Participant Program of the Wyss Institute for Biologically Inspired Engineering at Harvard University's Diagnostics Accelerator. The Wyss Institute at Harvard University is a translational research institute, developing disruptive innovation for healthcare and sustainability, powered by a multidisciplinary bioenginee.

Know Labs Joins the Industrial Participant Program of the Wyss Institute for Biologically Inspired Engineering at Harvard University

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International. With over 40 years of experience in commercializing innovation across related industries, Somogyi brings a wealth of expertise to lead the Company's “Skunkworks” Program and global patent licensing efforts. In his role, Somogyi will focus on identifying new applications of Know Labs' extens.

Know Labs Appoints Chris Somogyi as President, International

Know Labs, Inc. (NYSE:KNW ) Q2 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jordyn Hujar - Chief of Staff Ron Erickson - Chief Executive Officer Peter Conley - Chief Financial Officer Conference Call Participants Operator Greetings. Welcome to Know Labs's Second Quarter 2024 Earnings Conference Call.

Know Labs, Inc. (KNW) Q2 2024 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter of the fiscal year 2024 ended March 31, 2024. Financial Highlights: In Q2 FY 2024, Know Labs reported an operating loss of $4.73 million dollars, compared to an operating loss of $4.81 million dollars in Q2 FY 2023, a reduction in operating loss of 1.7%. This translates to Earnings Per Share of a loss of $0.07,.

Know Labs, Inc. Reports Second Quarter FY 2024 Results

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an oral abstract presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting in New Orleans, Louisiana on May 9, 2024 from 11:15 a.m. – 11:30 a.m. CDT. The Company will present an abstract titled, “Efficacy of a Non-Invasive Blood Glucose Monitor for Diabetes Management Using a Radiofrequency Se.

Know Labs to Present Clinical Research at the 2024 American Association of Clinical Endocrinology Annual Meeting

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its second quarter of the fiscal year 2024 ended on March 31, 2024, on May 15, 2024, beginning at 1:30 pm PT. Media and investors may access the live audio webcast at https://ir.knowlabs.co, beginning at 1:15 pm PT. Questions to the Company's management team can be submitted through.

Know Labs, Inc. to Host Review of Second Quarter Fiscal Year 2024 Results on May 15, 2024

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024. The Company will present results titled, “Non-Invasive Blood Glucose Monitoring Using a Radiofrequency Sensor and a Machine Learning Model.” These results demonstrated that novel data preprocessin.

Know Labs to Present Clinical Research at the 2024 American Physiology Summit

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study. The study assessed the accuracy of Know Labs' proprietary radiofrequency (RF) dielectric sensor in non-invasively measuring blood glucose in participants with prediabetes and Type 2 diabetes using venous blood as a comparative reference – resulting in an overall Mean Absolute Relative Di.

Know Labs' Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has entered into a funding agreement for an investment of up to $12 million, of which it has executed a $4 million close (the “Funding Agreement”) with Lind Global Fund II LP, an investment entity managed by The Lind Partners, a New York-based institutional fund manager (together, “Lind”). Ron Erickson, Chief Executive Officer and Chairman at Kn.

Know Labs Secures U.S. $12 Million Funding for Company's Further Execution on Its Clinical Research and Development Initiatives

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the KnowU™, its wearable non-invasive continuous glucose monitor (CGM). The Company announced its first prototype in June 2023. The KnowU is the result of an accelerated development process over the last eight months. The KnowU incorporates the sensor that the Company plans to submit to the FDA for clearance. This proprietary sensor has been tested.

Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor

Know Labs, Inc. (KNW) Q1 2024 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2023. Financial Highlights: In Q1 FY 2024, Know Labs reported a net loss of $3.45 million dollars, compared to a net loss of $3.82 million dollars in Q1 FY 2023, a reduction in net loss of 9.8%. This translates to Earnings Per Share of a loss of $0.04, better than the prior year quarter Earn.

News for Know Labs Inc Stock (KNW)